comprehensive -WSS

comprehensive

author：explore 2025-09-06 08:25:00 - browse：661

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： For AI in health care standards, federal regulators join with industry group

knowledge

WSS

Stem cell biologist probes earliest stages of human development

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

FDA endorses new sterilization method for medical devices

There's an unseen cost to disruptive road

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Printout prescription drug information shouldn’t go digital

entertainment

comprehensive

explore

Psychedelics group wrestles with new pharma identity

Biden's 'march

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The inclusion problem at the heart of rehabilitation research

Continuity nursing helped my family in our darkest PICU moments

To bolster infectious disease surveillance, genomics powerhouses team up

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Pregnant women don't need prenatal multivitamins, study concludes

BioMarin wins approval for gene therapy to treat hemophilia A

Biden's 'march

leisure time

Head of FDA's diagnostics center, who led through Covid, retires

Pumping milk in bathrooms at health conferences is common

HPV vaccine, cervical cancer study delivers historic results

Lack of health data on LGBTQ+ people has serious consequences

Biden's 'march

Florida health officials providing scant details on measles cases

knowledge

leisure time

focus

explore